Have you thought about

checking our FAQ ?

Who can benefit from the NFI services?

4 specific cases:
  • Foreign companies in all sectors looking to expand in Hauts-de-France
  • French companies with no site in Hauts-de-France
  • Hauts-de-France companies with a succession plan
  • Foreign-owned companies in Hauts-de-France with a development project
Our services are not intended for :
  • French or international self-employed entrepreneurs
  • French companies wishing to export
  • International companies seeking distribution networks only

Why as the help of Nord France Invest?

Nord France Invest provides you with completely tailored, free of charge and confidential support. We centralize all the information you need to analyze your project. We facilitate your process to find a site, partners or land. We organize site visits. We accelerate your networking with future regional partners. Find out more about the agency's services on this page.

What type of project can support you in?

The agency supports job-creating investment projects. The nature of projects varies according to 3 main categories:
  • Start-up projects
  • Expansion of existing sites in the region
  • takeovers of regional businesses by international companies.
Nord France Invest's services are not aimed at capital investments.
Check the FAQ
Contact

Do you have an expansion project?

Leave us your contact details and we’ll get back to you by e-mail.

This field is for validation purposes and should be left unchanged.
Top !
Home»success stories»A healthy outlook for biopharmaceuticals

A healthy outlook for biopharmaceuticals

Interview with GSK Vaccines

With 70,000 employees worldwide, 3,400 in France and 1,110 in the Hauts-de-France Region, GSK has made people the cornerstone of its development. Bolstered by a state-of-the-art manufacturing site located in the department of Nord, in which it has invested €600 million, this major player in the global biopharmaceutical industry has asserted its attachment to our region.
Date de publication Published on 03.04.2024

GSK – an overview

GSK (formerly GlaxoSmithKline) is a British biopharmaceutical company which focuses on four therapeutic areas: infectious diseases, HIV, oncology and immunology. The group employs over 70,000 people worldwide, including 3,400 in France and 9,000 in Belgium. Its worldwide sales topped £30 billion in 2022.

The Saint-Amand-les-Eaux manufacturing site

  • 1,110 employees
  • 100 countries receive a wide range of vaccines produced by GSK Vaccines
  • 146 million doses of GSK vaccines were filled in 2023

What role does the Saint-Amand-les-Eaux manufacturing site play
in GSK Vaccines' global strategy?

The Saint-Amand-les-Eaux site is relatively recent, as it was created only a decade or so ago. It’s the fruit of a major investment by GSK, which spent €600 million on designing and building a state-of-the-art plant equipped with the latest technology and boasting industry-leading facilities for secondary vaccine production. Our production is on the rise, reaching 130 million doses in 2022, and will continue to grow over the years to come. Our Nord-based site has taken on a predominant role at Group level, as we are one of the two or three largest GSK vaccine-production sites in the world in terms of volume.

How do you view your employees within an English-speaking group
which does not necessarily share our attitude towards work?

Every day I am truly amazed by the commitment shown by our employees at all levels, from our operators to our maintenance technicians, and from our automation engineers to our managerial staff. I’ve heard people say that this employee engagement based on a “can-do attitude” only exists in the United States or in English-speaking countries. But I can tell you that it also applies here!

Our employees in Hauts-de-France really want to work, make a difference and progress. This is a key factor in our development.

Do you have any new development projects
associated with your manufacturing site at Saint-Amand-Les-Eaux?

First of all, we’re rolling out a highly advanced project to build a training centre designed to upgrade our employees’ skills. After investing heavily in equipment and technology, we now want to invest in people. This is quite an original concept as it consists in recreating a production-line environment that will be similar to the real thing, but with a different purpose, since it will not be manufacturing real vaccines. This facility will enable staff to receive training and practice in a completely secure environment. This initial experience in a simulated environment will enable them to develop the right habits and the attitude required to improve their efficiency. We’re also developing other projects related to decarbonisation. The idea is to replace all our current boilers with hybrid boilers and heat pumps in order to substantially reduce our CO2 emissions.

How did the local and regional authorities influence your decision to set up a plant
in Saint-Amand-les-Eaux in Nord?

The local authorities – both the municipal council and the combined district council – welcomed us with open arms. Their goodwill and diligence in helping us with our endeavours have meant a great deal us. We’ve received powerful support from the local authorities during the good times, but also when we’ve run into difficulties, because such a major project is never a simple matter. The creation of our manufacturing site is the fruit of active collaboration and a close partnership between the GSK Group, Saint-Amand-Les-Eaux and the local authorities.

Without the regional and local authorities, we probably wouldn’t be here today. It should be noted that GSK had originally decided to make this investment in a different part of the world. In the end, France, the Hauts-de-France region, the department of Nord and the municipality of Saint-Amand-les-Eaux, were chosen. This result did not come about by chance.

What lessons have you learned from this collaboration
and can we draw any general conclusions from it?

I feel that economic decision-makers who want to set up in a business in a given area may underestimate the extent to which the local authorities can help them, but also the demands they can make. That’s why I strongly advise them to get in touch with them, because they can provide such effective and efficient support. I’ve mentioned the local authorities, but the Hauts-de-France region has also been actively involved. I’m strongly aware of the desire here to support international companies wishing to create a site in Hauts-de-France. We’ve been fortunate enough to receive support for our project from Nord France Invest.

Discover other
success-stories about

Horiba: groundbreaking innovation in the Hauts-de-France region
Health
Article

Horiba: groundbreaking innovation in the Hauts-de-France region

Announced at Choose France 2026, the investment by HORIBA further solidifies the Loos site’s role as a global hub for industrial Raman spectroscopy technologies and positions the Hauts-de-France region as a leading center for smart analytical instrumentation.
08-2026
Read more
Octopus Energy accelerates its expansion from its base in the Hauts-de-France region
Interview

Octopus Energy accelerates its expansion from its base in the Hauts-de-France region

In less than two years, Octopus Energy has opened two additional sites in the Hauts-de-France region. Why did this British energy supplier choose Lille and Amiens as the launch pad for its expansion in France? We take a closer look at a location strategy that highlights the region’s strengths.
07-2026
Read more
Agrati: from industrial recovery to lasting success in Hauts-de-France
Industry
Article

Agrati: from industrial recovery to lasting success in Hauts-de-France

Agrati, a family-owned Italian company specializing in fastening solutions for the automotive industry, took over two struggling industrial sites specializing in fasteners in Vieux-Condé and Fourmies back in 2010. Fifteen years later, the group is continuing its regional expansion with a new €15 million investment program. This trajectory is a concrete illustration of why Hauts-de-France ranks among Europe’s most attractive […]
07-2026
Read more
Agristo invests in Escaudœuvres to strengthen its production in Europe
Agrifood
Article

Agristo invests in Escaudœuvres to strengthen its production in Europe

The Belgian group Agristo, which specializes in frozen potato-based products, is setting up a new factory in Escaudœuvres, Hauts-de-France. The project is part of a strategy for expansion in Europe and is based on the conversion of an existing industrial site. It will create several hundred jobs and bring fresh momentum to the regional agrifood sector.
07-2026
Read more
SQWAD is reinventing outsourced customer relationship managment
Interview

SQWAD is reinventing outsourced customer relationship managment

Sqwad has introduced a new model for outsourcing customer relationship management. Alexis Barbay, the company’s chief operating officer, explains why this fast-growing startup—founded in 2021 and experiencing strong growth both in France and abroad—chose to set up operations in Lille.
07-2026
Read more
TMMF, Toyota’s “Made in France”
Automotive
Interview

TMMF, Toyota’s “Made in France”

Established in Hauts-de-France since 1991, the Japanese Manufacturer built the foundations of national success in the region and become the leading automotive manufacturer in France in 2022. Review of this return on investment for Toyota with Rodolphe Delaunay, its CEO.
06-2026
Read more